JP2014511844A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014511844A5 JP2014511844A5 JP2014501659A JP2014501659A JP2014511844A5 JP 2014511844 A5 JP2014511844 A5 JP 2014511844A5 JP 2014501659 A JP2014501659 A JP 2014501659A JP 2014501659 A JP2014501659 A JP 2014501659A JP 2014511844 A5 JP2014511844 A5 JP 2014511844A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- polypeptide
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161469388P | 2011-03-30 | 2011-03-30 | |
| US61/469,388 | 2011-03-30 | ||
| PCT/EP2012/055830 WO2012131053A1 (en) | 2011-03-30 | 2012-03-30 | Methods of treating immune disorders with single domain antibodies against tnf-alpha |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014511844A JP2014511844A (ja) | 2014-05-19 |
| JP2014511844A5 true JP2014511844A5 (enExample) | 2015-04-23 |
| JP6130350B2 JP6130350B2 (ja) | 2017-05-17 |
Family
ID=45952510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014501659A Active JP6130350B2 (ja) | 2011-03-30 | 2012-03-30 | ＴＮＦαに対する単一ドメイン抗体で免疫障害を処置する方法 |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JP6130350B2 (enExample) |
| KR (1) | KR20140018299A (enExample) |
| CN (2) | CN106039306A (enExample) |
| AU (1) | AU2012237287B2 (enExample) |
| MX (1) | MX361242B (enExample) |
| WO (1) | WO2012131053A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| NZ780183A (en) | 2011-06-23 | 2024-12-20 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| CA2849409A1 (en) * | 2011-09-23 | 2013-03-28 | Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa | Anti-tumor necrosis factor-alpha agents and uses thereof |
| HK1250040A1 (zh) | 2015-03-31 | 2018-11-23 | Sorriso Pharmaceuticals, Inc. | 多肽 |
| CA2981098A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Peptide construct having a protease-cleavable linker |
| JP6895421B2 (ja) | 2015-03-31 | 2021-06-30 | ブイエイチスクエアード リミテッド | ポリペプチド |
| CN111234027A (zh) | 2015-05-21 | 2020-06-05 | 哈普恩治疗公司 | 三特异性结合蛋白质及使用方法 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| BR112018073739A2 (pt) | 2016-05-20 | 2019-02-26 | Harpoon Therapeutics, Inc. | proteína de ligação de albumina sérica de domínio único |
| CN109641046B (zh) | 2016-05-20 | 2023-11-07 | 哈普恩治疗公司 | 单链可变片段cd3结合蛋白质 |
| ES2877548T3 (es) | 2016-06-02 | 2021-11-17 | Abbvie Inc | Agonista del receptor de glucocorticoides e inmunoconjugados del mismo |
| EP3519438A1 (en) | 2016-09-30 | 2019-08-07 | VHsquared Limited | Compositions |
| JP7215997B2 (ja) | 2016-11-23 | 2023-01-31 | ハープーン セラピューティクス，インク． | 前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法 |
| JP6812551B2 (ja) | 2016-11-23 | 2021-01-13 | ハープーン セラピューティクス，インク． | 前立腺特異的膜抗原結合タンパク質 |
| CN107674122A (zh) * | 2016-12-28 | 2018-02-09 | 天津天锐生物科技有限公司 | 一种识别人血清白蛋白的单域抗体 |
| US11535668B2 (en) | 2017-02-28 | 2022-12-27 | Harpoon Therapeutics, Inc. | Inducible monovalent antigen binding protein |
| CA3063359A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| CA3063362A1 (en) | 2017-05-12 | 2018-11-15 | Harpoon Therapeutics, Inc. | Msln targeting trispecific proteins and methods of use |
| UA129446C2 (uk) | 2017-10-13 | 2025-04-30 | Гарпун Терап'Ютікс, Інк. | Триспецифічні білки і способи їх застосування |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| AU2018374634A1 (en) | 2017-12-01 | 2020-05-28 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
| WO2019222283A1 (en) | 2018-05-14 | 2019-11-21 | Harpoon Therapeutics, Inc. | Binding moiety for conditional activation of immunoglobulin molecules |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| EP3856771A4 (en) | 2018-09-25 | 2022-06-29 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
| AR118191A1 (es) * | 2019-02-28 | 2021-09-22 | Celltrion Inc | MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa |
| EP3986931A1 (en) | 2019-06-21 | 2022-04-27 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| AU2020294980A1 (en) | 2019-06-21 | 2022-02-17 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| IL295448A (en) | 2020-02-21 | 2022-10-01 | Harpoon Therapeutics Inc | flt3 binding proteins and methods of use |
| CN120463762A (zh) | 2021-08-26 | 2025-08-12 | 映恩生物科技(上海)有限公司 | 一种甾体化合物及其缀合物 |
| CN120265663A (zh) * | 2022-09-21 | 2025-07-04 | 英脉生物医药(杭州)有限公司 | 靶向TNFα和IL-23的抗体及其用途 |
| AR133647A1 (es) | 2023-08-25 | 2025-10-22 | Proteologix Us Inc | Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| EP1997891A1 (en) | 1988-09-02 | 2008-12-03 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE144793T1 (de) | 1989-06-29 | 1996-11-15 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| GB9021679D0 (en) | 1990-10-05 | 1990-11-21 | Gorman Scott David | Antibody preparation |
| AU667460B2 (en) | 1990-10-05 | 1996-03-28 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
| AU8727291A (en) | 1990-10-29 | 1992-06-11 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| ATE439435T1 (de) | 1991-03-01 | 2009-08-15 | Dyax Corp | Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| WO1992019973A1 (en) | 1991-04-26 | 1992-11-12 | Surface Active Limited | Novel antibodies, and methods for their use |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| CA2131528C (en) | 1992-03-05 | 2004-07-13 | Philip E. Thorpe | Methods and compositions for targeting the vasculature of solid tumors |
| EP0656946B2 (en) | 1992-08-21 | 2010-03-31 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
| ATE352559T1 (de) | 1998-12-08 | 2007-02-15 | Biovation Ltd | Verfahren zur verminderung der immunogenität von proteinen |
| US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
| WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| US20050271663A1 (en) | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| US20030020733A1 (en) | 2001-07-24 | 2003-01-30 | Yin Memphis Zhihong | Computer display having selective area magnification |
| DK1517921T3 (da) | 2002-06-28 | 2006-10-09 | Domantis Ltd | Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf |
| EP3299393A1 (en) | 2002-11-08 | 2018-03-28 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| KR101025143B1 (ko) | 2002-12-31 | 2011-04-01 | 넥타르 테라퓨틱스 | 가수분해상으로 안정한 말레이미드－종결 중합체 |
| DK1639011T3 (da) | 2003-06-30 | 2009-02-16 | Domantis Ltd | Pegylerede enkelt-domæne antistoffer (dAb) |
| US7390872B2 (en) | 2003-09-24 | 2008-06-24 | Institut Pasteur | NF-κB peptides designed to disrupt NEMO oligomerization |
| CN103254309B (zh) * | 2005-05-18 | 2017-09-26 | 埃博灵克斯股份有限公司 | 针对肿瘤坏死因子α的改进的纳米体TM |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
| EP3011953A1 (en) * | 2008-10-29 | 2016-04-27 | Ablynx N.V. | Stabilised formulations of single domain antigen binding molecules |
| EP2346900A1 (en) * | 2008-10-29 | 2011-07-27 | Wyeth LLC | Methods for purification of single domain antigen binding molecules |
-
2012
- 2012-03-30 WO PCT/EP2012/055830 patent/WO2012131053A1/en not_active Ceased
- 2012-03-30 CN CN201610366021.4A patent/CN106039306A/zh active Pending
- 2012-03-30 AU AU2012237287A patent/AU2012237287B2/en not_active Ceased
- 2012-03-30 KR KR1020137027346A patent/KR20140018299A/ko not_active Ceased
- 2012-03-30 JP JP2014501659A patent/JP6130350B2/ja active Active
- 2012-03-30 MX MX2013011216A patent/MX361242B/es active IP Right Grant
- 2012-03-30 CN CN201280016811.XA patent/CN103547592A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014511844A5 (enExample) | ||
| US10442857B2 (en) | Anti-IL-17 antibodies | |
| AU2010225951B2 (en) | Pharmaceutical formulation containing improved antibody molecules | |
| JP7357038B2 (ja) | 改善されたｔｎｆ結合因子 | |
| AU2012285786B2 (en) | TNF -alpha antigen- binding proteins with increased FcRn binding | |
| AU2017319318B2 (en) | Anti-CD3 antibody formulations | |
| KR101044180B1 (ko) | 개량된 항체분자 | |
| AU2018200221A1 (en) | Polypeptide constructs and uses thereof | |
| JP2011514150A5 (enExample) | ||
| TW201043263A (en) | Stable high protein concentration formulations of human anti-TNF-alpha-antibodies | |
| JP2020502996A5 (enExample) | ||
| JP2017528132A (ja) | Ｉｌ−２３ａ及びｔｎｆ−アルファを標的とする化合物ならびにその使用 | |
| JP2012524071A5 (enExample) | ||
| JP2014237671A5 (enExample) | ||
| CA2898262A1 (en) | Tnf-alpha antigen-binding proteins | |
| CN106039306A (zh) | 使用针对TNFα的单结构域抗体治疗免疫病症的方法 | |
| RU2007142444A (ru) | Улучшенные нанотела против фактора некроза опухоли-альфа | |
| CA2959551A1 (en) | Anti-tnf-/anti-il-23 bispecific antibodies | |
| JP2011518857A5 (enExample) | ||
| EP2864356A1 (en) | Pharmaceutical formulation | |
| JP2020517671A5 (enExample) | ||
| CN114127108A (zh) | Il-17拮抗剂治疗自身免疫疾病的方法 | |
| TW202241505A (zh) | 抗il-17抗體治療自體免疫性疾病和炎症的方法 | |
| HK1225956A1 (en) | Methods of treating immune disorders with single domain antibodies against tnf-alpha |